BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30370392)

  • 21. Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
    Kostadinova L; Shive CL; Anthony DD
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
    Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients.
    Shahid M; Idrees M; Nasir B; Raja AJ; Raza SM; Amin I; Rasul A; Tayyab GU
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):788-94. PubMed ID: 24781355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals.
    Chuaypen N; Chittmittrapap S; Avihingsanon A; Siripongsakun S; Wongpiyabovorn J; Tanpowpong N; Tanaka Y; Tangkijvanich P
    Hepatol Res; 2021 May; 51(5):528-537. PubMed ID: 33615687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
    Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
    J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
    Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
    Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.
    Broquetas T; Herruzo-Pino P; Mariño Z; Naranjo D; Vergara M; Morillas RM; Forns X; Carrión JA
    Liver Int; 2021 Nov; 41(11):2733-2746. PubMed ID: 34525253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.
    Fabrizi F; Lunghi G; Finazzi S; Colucci P; Pagano A; Ponticelli C; Locatelli F
    Am J Kidney Dis; 2001 Nov; 38(5):1009-15. PubMed ID: 11684554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
    PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Soluble CD14 in Egyptian Patients with Chronic Hepatitis C: Its Relationship to Disease Progression and Response to Treatment.
    Medhat E; Salama H; Fouad H; Abd El Haleem H; Said M; El-Nahaas SM; Omran D
    J Interferon Cytokine Res; 2015 Jul; 35(7):563-8. PubMed ID: 25811314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of Shear Wave Elastography but Not Shear Wave Dispersion After Successful Hepatitis C Treatment With Direct-Acting Antiviral Agents.
    Su PY; Su WW; Wu LS; Hsu PK; Huang SP; Hsu YC
    J Ultrasound Med; 2021 Sep; 40(9):1919-1926. PubMed ID: 33400288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
    Farcomeni S; Moretti S; Fimiani C; Sulekova LF; Vescio F; Sernicola L; Maggiorella MT; Remoli AL; Picconi O; Mosca L; Esvan R; Biliotti E; Ciccozzi M; Sgarbanti M; Taliani G; Borsetti A
    Pathogens; 2021 Nov; 10(11):. PubMed ID: 34832642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection.
    Fouad SA; Esmat S; Omran D; Rashid L; Kobaisi MH
    World J Gastroenterol; 2012 Jun; 18(23):2988-94. PubMed ID: 22736923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease.
    Giannini E; Risso D; Botta F; Chiarbonello B; Fasoli A; Malfatti F; Romagnoli P; Testa E; Ceppa P; Testa R
    Arch Intern Med; 2003 Jan; 163(2):218-24. PubMed ID: 12546613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection.
    Ferra-Murcia S; Collado-Romacho AR; Nievas-Soriano BJ; Reche-Lorite F; Parrón-Carreño T
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
    J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.